July 15, 2015.
ANI Pharmaceuticals (Baudette, MN) has acquired 22 previously marketed generic drug products from Teva Pharmaceuticals for $25 million in cash and a percentage of future gross profits from product sales, IMS Health reports. The total market value for the 22 products is $650 million on a trailing 12-month basis.
Arthur S. Przybyl, President and CEO of ANI Pharmaceuticals, said the acquisition "meaningfully expands our product pipeline to 68 products with a total market value of $3.9B per IMS Health. We are pleased at the opportunity to extend our collaboration with Teva beyond the three transactions we have previously completed over the past 18 months."
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.